免疫療法對癌症病人及其家屬照顧者的身心衝擊與支持性照護需求

The Physical and Psychological Impacts and Supportive Care Needs of Patients With Cancer Undergoing Immunotherapy and Their Family Caregivers

10.6224/JN.202208_69(4).05

李芸湘(Yun-Hsiang LEE)；詹瑞君(Jui-Chun CHAN)；方圓媛(Yuan-Yuan FANG)

癌症 ； 免疫治療 ； 身心衝擊 ； 支持性照護需求 ； cancer ； immunotherapy ； physical and psychological impacts ； supportive care needs

護理雜誌

69卷4期（2022 / 08 / 01）

27 - 32

繁體中文

近年來新興治療的篷勃發展，免疫治療為晚期癌症病人帶來延長存活期的希望，然而，在免疫治療抗癌歷程中，病人除了要面對病情變化、身心症狀外，還需面對特定於免疫治療的副作用及成效問題，這些都可能使病人及其家屬照護者更常處於害怕、焦慮、憂鬱或不確定感等複雜情緒之中，進而產生特定於免疫治療期間未被滿足的照護需求問題，由於現階段針對免疫治療期間，晚期癌症病人及其家屬照顧者的身心衝擊與支持性照護需求問題的論述文章相當有限。故本文將針對以下內容進行說明：（一）癌症免疫治療簡介；（二）免疫治療病人與家屬照顧者之身心衝擊情形；（三）免疫治療病人與家屬照顧者之支持性照護需求現況；（四）免疫治療病人與家屬照顧者支持性照護需求評估與措施，期望透過本文能幫助未來臨床上醫護人員瞭解面對晚期癌症病人及其家屬照顧者免疫治療期間身心衝擊和支持性照護需求，同時，建議未來可提供或發展的適切措施，進而提升他們的生活品質，增進臨床護理照護品質。

New, science-based cancer treatments have proliferated in recent years. Immunotherapy provides new hope for prolonging survival in patients with advanced-stage cancers. However, patients with cancer must not only face their disease progression, physical, and psychological symptoms, but also deal with the side effects and efficacy of immunotherapy. Patients with cancer may experience complex emotions such as fear, anxiety, depression, or uncertainty relatively frequently and may have many unmet care needs specific to immunotherapy. However, articles on the physical and psychological impacts and supportive care needs experienced by patients with advanced-stage cancers undergoing immunotherapy and their family caregivers are limited in the literature. Thus, this paper was developed to present (1) a brief introduction to cancer immunotherapy; (2) the physical and psychological impacts experienced by patients with cancer undergoing immunotherapy and their caregivers; (3) the status of the supportive care needs of patients and family caregivers during the immunotherapy process; and (4) an assessment of and intervention to address the supportive care needs of these patients with cancer and their caregivers. We hope this article will help clinical healthcare providers understand the physical and psychological impacts and supportive care needs of advanced patients with cancer and their family caregivers during the immunotherapy process. Furthermore, we suggest that appropriate medical care be provided or developed in the future to improve their quality of life during the immunotherapy process and to enhance clinical practices.

1. 詹瑞君、高子媗、陳璵帆、邱文姿、李芸湘（2021）．癌症病人接受免疫治療之臨床評估與照護：以免疫相關皮膚不良事件為例．腫瘤護理雜誌，21（2），21–34。[Chan, J.-C., Gao, Z.-X., Chen, Y.-F., Chiu, W.-T., & Lee, Y.-H. (2021). Clinical assessment and nursing care of patients with cancer undergoing immunotherapy: An example for immune-related cutaneous adverse events. The Journal of Oncology Nursing, 21(2), 21–34.] https://doi.org/10.6880/TJON.202112_21(2).03
   連結：
2. Adashek, J. J., & Subbiah, I. M. (2020). Caring for the caregiver: A systematic review characterising the experience of caregivers of older adults with advanced cancers. ESMO Open, 5(5), Article e000862. https://doi.org/10.1136/esmoopen-2020-000862
   連結：
3. Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D. I., Culine, S., Sternberg, C. N., Mai, Y., Poehlein, C. H., Perini, R. F., & Bajorin, D. F. (2017). Pembrolizumab as second-line therapy for advanced urothelial carcinoma. The New England Journal of Medicine, 376(11), 1015–1026. https://doi.org/10.1056/NEJMoa1613683
   連結：
4. Chen, S.-C., Lai, Y.-H., Liao, C.-T., Huang, B.-S., Lin, C.-Y., Fan, K.-H., & Chang, J. T.-C. (2014). Unmet supportive care needs and characteristics of family caregivers of patients with oral cancer after surgery. Psycho-Oncology, 23(5), 569–577. https://doi.org/10.1002/pon.3458
   連結：
5. Fletcher, B. S., Miaskowski, C., Given, B., & Schumacher, K. (2012). The cancer family caregiving experience: An updated and expanded conceptual model. European Journal of Oncology Nursing, 16(4), 387–398. https://doi.org/10.1016/j.ejon.2011.09.001
   連結：
6. Garrett, N. F. M. D. S., da Costa, A. C. C., Damiani, G., & Vasques, C. I. (2020). Patients with lung cancer undergoing immune checkpoint inhibitors: A meta-analysis of dermatological toxicities. Critical Reviews in Oncology/Hematology, 152, Article 102983. https://doi.org/10.1016/j.critrevonc.2020.102983
   連結：
7. Girgis, A., Lambert, S. D., McElduff, P., Bonevski, B., Lecathelinais, C., Boyes, A., & Stacey, F. (2013). Some things change, some things stay the same: A longitudinal analysis of cancer caregivers’ unmet supportive care needs. Psycho-Oncology, 22(7), 1557–1564. https://doi.org/10.1002/pon.3166
   連結：
8. Hu, C.-C., You, K.-L., Tsai, L.-Y., Fang, Y.-Y., Jhang, S.-Y., Lou, P.-J., Wang, C.-P., Ko, J.-Y., Lee, Y.-H., & Lai, Y.-H. (2019). Validation of the supportive care needs survey screening tool Chinese version for patients with head and neck cancer in Taiwan. The Journal of Nursing Research, 27(6), Article e50. https://doi.org/10.1097/JNR.0000000000000360
   連結：
9. Johansen, S., Cvancarova, M., & Ruland, C. (2018). The effect of cancer patients’ and their family caregivers’ physical and emotional symptoms on caregiver burden. Cancer Nursing, 41(2), 91–99. https://doi.org/10.1097/NCC.0000000000000493
   連結：
10. Lee, Y.-H., Liao, Y.-C., Liao, W.-Y., Shun, S.-C., Liu, Y.-C., Chan, J.-C., Yu, C.-J., Yang, P.-C., & Lai, Y.-H. (2013). Anxiety, depression and related factors in family caregivers of newly diagnosed lung cancer patients before first treatment. Psycho-Oncology, 22(11), 2617–2623. https://doi.org/10.1002/pon.3328
    連結：
11. Levy, D., Dhillon, H. M., Lomax, A., Marthick, M., McNeil, C., Kao, S., & Lacey, J. (2019). Certainty within uncertainty: A qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy. Supportive Care in Cancer, 27(5), 1845–1852. https://doi.org/10.1007/s00520-018-4443-3
    連結：
12. McNutt, M. (2013). Cancer immunotherapy. Science, 342(6165), 1417. https://doi.org/10.1126/science.1249481
    連結：
13. Nesline, M. K., Knight, T., Colman, S., & Patel, K. (2020). Economic burden of checkpoint inhibitor immunotherapy for the treatment of non–small cell lung cancer in US clinical practice. Clinical Therapeutics, 42(9), 1682–1698.e7. https://doi.org/10.1016/j.clinthera.2020.06.018
    連結：
14. Niedzwiedz, C. L., Knifton, L., Robb, K. A., Katikireddi, S. V., & Smith, D. J. (2019). Depression and anxiety among people living with and beyond cancer: A growing clinical and research priority. BMC Cancer, 19(1), Article 943. https://doi.org/10.1186/s12885-019-6181-4
    連結：
15. Oechsle, K., Ullrich, A., Marx, G., Benze, G., Heine, J., Dickel, L.-M., Zhang, Y., Wowretzko, F., Wendt, K. N., Nauck, F., Bokemeyer, C., & Bergelt, C. (2019). Psychological burden in family caregivers of patients with advanced cancer at initiation of specialist inpatient palliative care. BMC Palliative Care, 18(1), Article 102. https://doi.org/10.1186/s12904-019-0469-7
    連結：
16. Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018). Immune-related adverse events associated with immune checkpoint blockade. The New England Journal of Medicine, 378(2), 158–168. https://doi.org/10.1056/NEJMra1703481
    連結：
17. Reck, M., Rodriguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., Hotta, K., Leiby, M. A., Lubiniecki, G. M., Shentu, Y., Rangwala, R., & Brahmer, J. R. (2016). Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. The New England Journal of Medicine, 375(19), 1823–1833. https://doi.org/10.1056/NEJMoa1606774
    連結：
18. Schulz, R., & Beach, S. R. (1999). Caregiving as a risk factor for mortality: The caregiver health effects study. JAMA, 282(23), 2215–2219. https://doi.org/10.1001/jama.282.23.2215
    連結：
19. Teixeira, R. J., Applebaum, A. J., Bhatia, S., & Brandão, T. (2018). The impact of coping strategies of cancer caregivers on psychophysiological outcomes: An integrative review. Psychology Research and Behavior Management, 11, 207–215. https://doi.org/10.2147/PRBM.S164946
    連結：
20. Thorne, S. E., Oliffe, J. L., Oglov, V., & Gelmon, K. (2013). Communication challenges for chronic metastatic cancer in an era of novel therapeutics. Qualitative Health Research, 23(7), 863–875. https://doi.org/10.1177/1049732313483926
    連結：
21. Villadolid, J., & Amin, A. (2015). Immune checkpoint inhibitors in clinical practice: Update on management of immune-related toxicities. Translational Lung Cancer Research, 4(5), 560–575. https://doi.org/10.3978/j.issn.2218-6751.2015.06.06
    連結：
22. Walker, M. S., Pohl, G. M., Houts, A. C., Peltz, G., Miller, P. J. E., Schwartzberg, L. S., Stepanski, E. J., & Marciniak, M. (2017). Analysis of the psychological impact of cancer-related symptoms on patients with non-small cell lung cancer. Psycho-Oncology, 26(6), 755–762. https://doi.org/10.1002/pon.4071
    連結：
23. Wang, T., Molassiotis, A., Chung, B. P. M., & Tan, J.-Y. (2018). Unmet care needs of advanced cancer patients and their informal caregivers: A systematic review. BMC Palliative Care, 17(1), Article 96. https://doi.org/10.1186/s12904-018-0346-9
    連結：
24. 高子媗（2021）．家屬照顧者於癌症病人接受免疫治療期間之支持性照護需求及其相關因素探討〔未發表的碩士論文〕．國立臺灣大學。[Gao, Z.-X. (2021). Related factors and supportive care needs in family caregivers with cancer patients undergoing immunotherapy [Unpublished master’s thesis]. National Taiwan University.]
25. 陳盈吟、陳崇裕（2019）．癌症免疫治療新進展．中西整合醫學雜誌，21（1），1–7。[Chen, Y.-Y., & Chen, C.-Y. (2019). Update of immunotherapy. Journal of Integrated Chinese and Western Medicine, 21(1), 1–7.]
26. 衛生福利部中央健康保險署（2022，4月25日）．「藥品給付規定」第9節抗癌瘤藥物。https://bit.ly/3H3Rn1v [National Health Insurance Administration, Ministry of Health and Welfare, Taiwan, ROC. (2022, April 25). “Drug payment regulations”, Section 9, antineoplastics. https://bit.ly/3H3Rn1v]
27. Cancer Australia. (n.d.). Cancer supportive care needs. Retrieved May 10, 2022, from https://www.edcan.org.au/edcan-learning-resources/supporting-resources/supportive-care/cancer-supportive-care-needs
28. Tattersall, I. W., & Leventhal, J. S. (2020). Cutaneous toxicities of immune checkpoint inhibitors: The role of the dermatologist. The Yale Journal of Biology and Medicine, 93(1), 123–132.